Importantly, these insights suggest that keratinocytic differentiation markers, such as PERP, could serve as prognostic indicators of tumor behavior, while therapeutic strategies targeting p63-mediated pathways may offer novel avenues to mitigate MCC plasticity and treatment resistance. The gene discussed is MCC; the disease is neoplasm.